Ken Griffin Pyxis Oncology, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 19,500 shares of PYXS stock, worth $23,400. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,500
Previous 41,500
53.01%
Holding current value
$23,400
Previous $64,000
70.31%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding PYXS
# of Institutions
90Shares Held
23.2MCall Options Held
138KPut Options Held
30.9K-
Laurion Capital Management LP New York, NY3.63MShares$4.35 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$3.34 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.49MShares$2.98 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.44MShares$2.92 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.11MShares$1.33 Million0.0% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $42.1M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...